Aspirin for primary prevention of CVD in CKD: where do we stand?

Br J Gen Pract. 2019 Nov 28;69(689):590-591. doi: 10.3399/bjgp19X706661. Print 2019 Dec.

Authors

Hugh Gallagher¹, Mark Lown², Ahmet Fuat³, Paul Roderick²

Affiliations

¹ SW Thames Renal Unit, Epsom and St Helier NHS Trust, Renal Unit, St Helier Hospital, Carshalton, Sutton.
² Primary Care and Population Sciences, University of Southampton, Aldermoor Health Centre, Southampton.
³ Carmel Medical Practice, Darlington; Honorary Professor of Cardiology, School for Health, Durham University, Durham, Stockton-on-Tees.

No abstract available

Publication types

Editorial
Comment

MeSH terms

Aspirin
Cardiovascular Diseases*
Humans
Primary Prevention
Renal Insufficiency, Chronic*
Secondary Prevention
Vascular Diseases*

Substances

Aspirin

Grants and funding